Abstract
Breast cancer therapy involves a multidisciplinary approach comprising surgery, radiotherapy, neoadjuvant and adjuvant therapy. Effective therapy of breast cancer requires maximum therapeutic efficacy, with minimal undesirable effects to ensure a good quality of life for patients. The carefully selected combination of therapeutic interventions provides patients with the opportunity to derive maximum benefit from therapy while minimizing or eliminating recurrence, resistance and toxic effects, as well as ensuring that patients have a good quality of life. This review discusses therapeutic options for breast cancer treatments and various combinations that had been previously exploited. The review will also give an insight into the potential application of the nanotechnology platform for codelivery of therapeutics in breast cancer therapy.
Keywords: Breast cancer, chemotherapy, combination therapy, early breast cancer, metastatic breast cancer, nanotechnology, radiotherapy, surgery.
Graphical Abstract
[2]
Torre LA, Siegel RL, Ward EM, Jemal A. Global cancer incidence and mortality rates and trends: an update. Cancer Epidemiol Biomarkers Prev 2016; 25(1): 16-27.
[3]
Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000; 406(6797): 747-52.
[4]
Prat A, Pineda E, Adamo B, et al. Clinical implications of the intrinsic molecular subtypes of breast cancer. Breast 2015; 24: S26-35.
[5]
Matta J, Ortiz C, Encarnacion J, Dutil J, Suarez E. Variability in dna repair capacity levels among molecular breast cancer subtypes: triple negative breast cancer shows lowest repair. Int J Mol Sci 2017; 18(7)
[6]
Cheang MCU, Voduc D, Bajdik C, et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 2008; 14(5): 1368-76.
[7]
Leidy J, Khan A, Kandil D. Basal-like breast cancer: update on clinicopathologic, immunohistochemical, and molecular features. Arch Pathol Lab Med 2014; 138(1): 37-43.
[8]
Lousberg L, Collignon J, Jerusalem G. Resistance to therapy in estrogen receptor positive and human epidermal growth factor 2 positive breast cancers: progress with latest therapeutic strategies. Ther Adv Med Oncol 2016; 8(6): 429-49.
[9]
Van’t Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415(6871): 530-6.
[10]
Sotiriou C, Neo S-Y, McShane LM, et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 2003; 100(18): 10393-8.
[11]
Prat A, Carey LA, Adamo B, et al. Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancer. J Natl Cancer Inst 2014; 106(8): 152.
[12]
Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344(11): 783-92.
[13]
Blok EJ, Derks MGM, van der Hoeven JJM, van de Velde CJH, Kroep JR. Extended adjuvant endocrine therapy in hormone-receptor positive early breast cancer: current and future evidence. Cancer Treat Rev 2015; 41(3): 271-6.
[14]
Nuciforo P, Thyparambil S, Aura C, et al. High Her2 protein levels correlate with increased survival in breast cancer patients treated with anti-Her2 therapy. Mol Oncol 2016; 10(1): 138-47.
[15]
Chew HK. Adjuvant therapy for breast cancer: who should get what? West J Med 2001; 174(4): 284-7.
[16]
De Matteis A, Nuzzo F, D’Aiuto G, et al. Docetaxel plus epidoxorubicin as neoadjuvant treatment in patients with large operable or locally advanced carcinoma of the breast. Cancer 2002; 94(4): 895-901.
[18]
Wang M, Hou L, Chen M, et al. Neoadjuvant chemotherapy creates surgery opportunities for inoperable locally advanced breast cancer. Sci Rep 2017; 7: 44673.
[19]
Tanaka S, Iwamoto M, Kimura K, et al. Phase ii study of neoadjuvant anthracycline-based regimens combined with nanoparticle albumin-bound paclitaxel and trastuzumab for human epidermal growth factor receptor 2-positive operable breast cancer. Clin Breast Cancer 2015; 15(3): 191-6.
[20]
Kummel S, Holtschmidt J, Loibl S. Surgical treatment of primary breast cancer in the neoadjuvant setting. Br J Surg 2014; 101(8): 912-24.
[21]
Neuman HB, Morrogh M, Gonen M, Van ZKJ, Morrow M, King TA. Stage IV breast cancer in the era of targeted therapy: does surgery of the primary tumor matter? Cancer 2010; 116(5): 1226-33.
[22]
Hennigs A, Riedel F, Marmé F, et al. Changes in chemotherapy usage and outcome of early breast cancer patients in the last decade. Breast Cancer Res Treat 2016; 160(3): 491-9.
[23]
Darby S, McGale P, Correa C, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet 2011; 378(9804): 1707-16.
[24]
Roy V, Pockaj BA, Allred JB, et al. A Phase II trial of docetaxel and carboplatin administered every 2 weeks as preoperative therapy for stage Ii or Iii breast cancer: NCCTG study N0338. J Clin Oncol 2013; 36(6): 540-4.
[25]
Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 2002; 347(16): 1233-41.
[26]
McLaughlin SA. Surgical management of the breast: breast conservation therapy and mastectomy. Surg Clin North Am 2013; 93(2): 411-28.
[27]
Shaitelman SF, Kim LH. Accelerated partial-breast irradiation: the current state of our knowledge. Oncology 2013; 27(4): 329-42.
[28]
Hopwood P, Haviland JS, Sumo G, Mills J, Bliss JM, Yarnold JR. Comparison of patient-reported breast, arm, and shoulder symptoms and body image after radiotherapy for early breast cancer: 5-year follow-up in the randomised standardisation of breast radiotherapy (start) trials. Lancet Oncol 2010; 11(3): 231-40.
[29]
Sardaro A, Petruzzelli MF, D’Errico MP, Grimaldi L, Pili G, Portaluri M. Radiation-induced cardiac damage in early left breast cancer patients: risk factors, biological mechanisms, radiobiology, and dosimetric constraints. Radiother Oncol 2012; 103(2): 133-42.
[30]
Rakhra S, Bethke K, Strauss J, et al. Risk factors leading to complications in early-stage breast cancer following breast-conserving surgery and intraoperative radiotherapy. Ann Surg Oncol 2016; 24(5): 1258-61.
[31]
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365(9472): 1687-717.
[32]
Houssami N, Macaskill P, von Minckwitz G, Marinovich ML, Mamounas E. Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy. Eur J Cancer 2012; 48(18): 3342-54.
[33]
Rashid OM, Takabe K. Does removal of the primary tumor in metastatic breast cancer improve survival? J Womens Health Wellness 2014; 23(2): 184-8.
[35]
Sachdev JC, Jahanzeb M. Use of cytotoxic chemotherapy in metastatic breast cancer: putting taxanes in perspective. Clin Breast Cancer 2016; 16(2): 73-81.
[36]
Vrdoljak E, Boban M, Omrcen T, Hrepic D, Fridl-Vidas V, Boskovic L. Combination of capecitabine and mitomycin C as first-line treatment in patients with metastatic breast cancer. Neoplasma 2011; 58(2): 172-8.
[37]
Tanabe M. Combination chemotherapy of mitomycin C and methotrexate was effective on metastatic breast cancer resistant to eribulin, vinorelbine, and bevacizumab after anthracycline, taxane, and capecitabine. Case Rep Oncol 2016; 9(2): 422-6.
[38]
Greenberg PA, Hortobagyi GN, Smith TL, Ziegler LD, Frye DK, Buzdar AU. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 1996; 14(8): 2197-205.
[39]
Tomiak E, Piccart M, Mignolet F, et al. Characterisation of complete responders to combination chemotherapy for advanced breast cancer: a retrospective eortc breast group study. Eur J Cancer 1996; 32a(11): 1876-87.
[40]
Chou T-C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Biochem Behav 2006; 58(3): 621-81.
[41]
Foucquier J, Guedj M. Analysis of drug combinations: current methodological landscape. Pharmacol Res Perspect 2015; 3(3): e00149.
[42]
Yuan R, Lin Y. Traditional Chinese medicine: an approach to scientific proof and clinical validation. Pharmacol Ther 2000; 86(2): 191-8.
[43]
Bonadonna G, Brusamolino E, Valagussa P, et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 1976; 294(8): 405-10.
[44]
Pronzato P, Rondini M. First line chemotherapy of metastatic breast cancer. Ann Oncol 2006; 17: v165-8.
[45]
Anampa J, Makower D, Sparano JA. Progress in adjuvant chemotherapy for breast cancer: an overview. BMC Med 2015; 13(1): 195.
[46]
Keith CT, Borisy AA, Stockwell BR. Multicomponent therapeutics for networked systems. Nat Rev Drug Discov 2005; 4(1): 71-8.
[47]
Heys SD, Hutcheon AW, Sarkar TK, et al. Neoadjuvant docetaxel in breast cancer: 3-Year Survival Results from the Aberdeen trial. Clin Breast Cancer 2002; 3: S69-74.
[48]
Malhotra V, Dorr VJ, Lyss AP, et al. Neoadjuvant and adjuvant chemotherapy with doxorubicin and docetaxel in locally advanced breast cancer. Clin Breast Cancer 2004; 5(5): 377-84.
[49]
Colleoni M, Goldhirsch A. Neoadjuvant chemotherapy for breast cancer: any progress? Lancet Oncol 2014; 15(2): 131-2.
[50]
Kaufmann M, von Minckwitz G, Mamounas EP, et al. Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Ann Surg Oncol 2012; 19(5): 1508-16.
[51]
Bear HD, Anderson S, Brown A, et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from national surgical adjuvant breast and bowel project protocol B-27. J Clin Oncol 2003; 21(22): 4165-74.
[52]
Earl HM, Vallier AL, Hiller L, et al. Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (neo-tango): an open-label, 2x2 factorial randomised phase 3 trial. Lancet Oncol 2014; 15(2): 201-12.
[53]
von Minckwitz G, Untch M, Blohmer JU, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 2012; 30(15): 1796-804.
[54]
Buzdar AU, Suman VJ, Meric-Bernstam F, et al. fluorouracil, epirubicin, and cyclophosphamide (fec-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by fec-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial. Lancet Oncol 2013; 14(13): 1317-25.
[55]
Abrams JS. Adjuvant therapy for breast cancer--results from the USA consensus conference. Breast Cancer 2001; 8(4): 298-304.
[56]
Early breast cancer trialists’ collaborative group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Early breast cancer trialists’ collaborative group. Lancet 1998; 352(9132): 930-42.
[57]
Fisher B, Dignam J, Wolmark N, et al. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst 1997; 89(22): 1673-82.
[58]
Fisher B, Redmond C, Wickerham DL, et al. Doxorubicin-containing regimens for the treatment of stage ii breast cancer: the national surgical adjuvant breast and bowel project experience. J Clin Oncol 1989; 7(5): 572-82.
[59]
Fisher B, Brown AM, Dimitrov NV, et al. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the national surgical adjuvant breast and bowel project B-15. J Clin Oncol 1990; 8(9): 1483-96.
[60]
Hortobagyi GN, Blumenschein GR, Spanos W, et al. Multimodal treatment of locoregionally advanced breast cancer. Cancer 1983; 51(5): 763-8.
[61]
French Epirubicin Study Group. A prospective randomized phase Iii trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. French epirubicin study group. J Clin Oncol 1988; 6(4): 679-88.
[62]
French adjuvant study group. Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French adjuvant study group 05 randomized trial. J Clin Oncol 2001; 19(3): 602-11.
[63]
Creagan ET, Green SJ, Ahmann DL, Ingle JN, Edmonson JH, Jr RFM. A phase Iii clinical trial comparing the combination cyclophosphamide, adriamycin, cisplatin with cyclophosphamide, 5-fluorouracil, prednisone in patients with advanced breast cancer. J Clin Oncol 1984; 2(11): 1260-5.
[64]
Saphner T, Tormey DC, Albertini M. Continuous infusion 5-fluorouracil with escalating doses of intermittent cisplatin and etoposide. A phase I study. Cancer 1991; 68(11): 2359-62.
[65]
Trump DL, Ettinger DS, MD A Doxorubicin. vincristine, and cis-diamminedichloroplatinum (Ii) therapy in patients with advanced breast cancer. Med Pediatr Oncol 981(9): 1-3.
[66]
Martoni A, Tomasi L, Farabegoli G, et al. A phase II study of 4′-epi-doxorubicin plus cis-platinum in advanced solid tumors. Eur J Cancer Clin Oncol 1984; 20(1): 11-7.
[67]
Smith IE, Talbot DC. Cisplatin and Its analogues in the treatment of advanced breast cancer: a review. Br J Cancer 1992; 65(6): 787-93.
[68]
Bonneterre J, Dieras V, Tubiana-Hulin M, et al. Phase II multicentre randomised study of docetaxel plus epirubicin vs. 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancer. Br J Cancer 2004; 91(8): 1466-71.
[69]
Donehower RC, Rowinsky EK. An overview of experience with taxol* (paclitaxel) in the U.S.A. Cancer Treat Rev 1993; 19: 63-78.
[70]
Hortobagyi GN. Paclitaxel-based combination chemotherapy for breast cancer. Oncology 1997; 11: 29-37.
[71]
Gianni L, Munzone E, Capri G, et al. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 1995; 13(11): 2688-99.
[72]
Wasserheit C, Frazein A, Oratz R, et al. Phase ii trial of paclitaxel and cisplatin in women with advanced breast cancer: an active regimen with limiting neurotoxicity. J Clin Oncol 1996; 14(7): 1993-9.
[73]
Gelmon KA, O’Reilly SE, Tolcher AW, et al. Phase I/II trial of biweekly paclitaxel and cisplatin in the treatment of metastatic breast cancer. J Clin Oncol 1996; 14(4): 1185-91.
[74]
Esteva FJ, Valero V, Pusztai L, Boehnke-Michaud L, Buzdar AU, Hortobagyi GN. Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond. Oncologist 2001; 6(2): 133-46.
[75]
Nabholtz J-M, Falkson C, Campos D, et al. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III Trial. J Clin Oncol 2003; 21(6): 968-75.
[76]
Smith RE, Anderson SJ, Lembersky BC, Brown A, Mamounas EP. Phase ii trial of a doxorubicin/docetaxel doublet for locally advanced and metastatic breast cancer: results from national surgical adjuvant breast and bowel project trial Bp-57. Clin Breast Cancer 2004; 5(3): 208-15.
[77]
Sessa C, Pagani O. Docetaxel and epirubicin in advanced breast cancer. Oncologist 2001; 6: 13-6.
[78]
Trudeau ME, Chapman J-AW, Guo B, et al. A phase I/II trial of epirubicin and docetaxel in locally advanced breast cancer (labc) on 2-weekly or 3-weekly schedules: NCIC CTG MA.22. Springerplus 2015; 4(1): 631.
[79]
Park SH, Cho EK, Bang S-M, Shin DB, Lee JH, Lee YD. Docetaxel plus cisplatin is effective for patients with metastatic breast cancer resistant to previous anthracycline treatment: a phase II clinical trial. BMC Cancer 2005; 5: 21.
[81]
Colozza M, Tonato M, Grignani F, Davis S. Low-dose mitomycin and weekly low-dose doxorubicin combination chemotherapy for patients with metastatic breast carcinoma previously treated with cyclophosphamide, methotrexate, and 5-fluorouracil. Cancer 1988; 62(2): 262-5.
[82]
Panasci L, Shenouda G, Begin L, Pollak M, Reinke A, Margolese R. Mitomycin C and mitoxantrone chemotherapy for advanced breast cancer: efficacy with minimal gastrointestinal toxicity and alopecia. Cancer Chemother Pharmacol 1990; 26(6): 457-60.
[83]
Ospovat I, Siegelmann-Danieli N, Grenader T, Hubert A, Hamburger T, Peretz T. Mitomycin C and vinblastine: an active regimen in previously treated breast cancer patients. Tumori 2009; 95(6): 683-6.
[84]
Tanabe M, Ito Y, Tokudome N, et al. Possible use of combination chemotherapy with mitomycin C and methotrexate for metastatic breast cancer pretreated with anthracycline and taxanes. Breast Cancer 2009; 16(4): 301.
[85]
Fukuda T, Tanabe M, Kobayashi K, et al. Combination chemotherapy with mitomycin C and methotrexate is active against metastatic HER2-negative breast cancer even after treatment with anthracycline, taxane, capecitabine, and vinorelbine. Springerplus 2015; 4(1): 376.
[86]
Gómez HL, Neciosup S, Tosello C, et al. A phase II randomized study of lapatinib combined with capecitabine, vinorelbine, or gemcitabine in patients with HER2-positive metastatic breast cancer with progression after a taxane (latin american cooperative oncology group 0801 study). Clin Breast Cancer 2016; 16(1): 38-44.
[87]
Yardley DA, Ward PJ, Daniel BR, et al. Panitumumab, gemcitabine, and carboplatin as treatment for women with metastatic triple-negative breast cancer: a sarah cannon research institute phase II trial. Clin Breast Cancer 2016; 16(5): 349-55.
[88]
Cinieri S, Chan A, Altundag K, et al. Final results of the randomized phase Ii norcap-ca223 trial comparing first-line all-oral versus taxane-based chemotherapy for HER2-negative metastatic breast cancer. Clin Breast Cancer 2017; 17(2): 91-9.
[89]
Schroder L, Rack B, Sommer H, et al. Toxicity assessment of a phase Iii study evaluating fec-doc and fec-doc combined with gemcitabine as an adjuvant treatment for high-risk early breast cancer: the success-a trial. Geburtshilfe Frauenheilkd 2016; 76(5): 542-50.
[90]
Earl HM, Hiller L, Howard HC, et al. Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tango): final 10-year follow-up of an open-label, randomised, phase 3 trial. Lancet Oncol 2017; 18(6): 755-69.
[91]
Lu X, Xiao L, Wang L, Ruden DM. Hsp90 inhibitors and drug resistance in cancer: the potential benefits of combination therapies of Hsp90 inhibitors and other anti-cancer drugs. Biochem Pharmacol 2012; 83(8): 995-1004.
[92]
Modi S, Stopeck AT, Gordon MS, et al. Combination of trastuzumab and tanespimycin (17-aag, kos-953) is safe and active in trastuzumab-refractory her-2-overexpressing breast cancer: a phase I dose-escalation study. J Clin Oncol 2007; 25(34): 5410-7.
[93]
Modi S, Stopeck A, Linden H, et al. Hsp90 inhibition is effective in breast cancer: a phase ii trial of tanespimycin (17-aag) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab. Clin Cancer Res 2011; 17(15): 5132-9.
[94]
Baselga J, Cortés J, Kim S-B, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. new england journal of medicine. N Engl J Med 2012; 366(2): 109-19.
[95]
Swain SM, Kim S-B, Cortés J, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (Cleopatra study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 2013; 14(6): 461-71.
[96]
Swain SM, Ewer MS, Cortés J, et al. Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in Cleopatra: a randomized, double-blind, placebo-controlled phase III Study. Oncologist 2013; 18(3): 257-64.
[97]
Swain SM, Baselga J, Kim SB. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 2015; 372(8): 724-34.
[98]
Bhaskar S, Tian F, Stoeger T, et al. Multifunctional nanocarriers for diagnostics, drug delivery and targeted treatment across blood-brain barrier: perspectives on tracking and neuroimaging. Part Fibre Toxicol 2010; 7(1): 3.
[99]
Drbohlavova J, Chomoucka J, Adam V, et al. Nanocarriers for anticancer drugs-new trends in nanomedicine. Curr Drug Metab 2013; 14(5): 547-64.
[100]
Su H, Wang Y, Gu Y, Bowman L, Zhao J, Ding M. Potential applications and human biosafety of nanomaterials used in nanomedicine. J Appl Toxicol 2018; 38(1): 3-24.
[101]
Davis ME, Chen Z. DM. S. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 2008; 7(9): 771-82.
[102]
Ma L, Kohli M, Smith A. Nanoparticles for combination drug therapy. ACS Nano 2013; 7(11): 9518-25.
[103]
Shuhendler AJ, Cheung RY, Manias J, Connor A, Rauth AM, Wu XY. A novel doxorubicin-mitomycin c co-encapsulated nanoparticle formulation exhibits anti-cancer synergy in multidrug resistant human breast cancer cells. Breast Cancer Res Treat 2009; 119(2): 255.
[104]
Prasad P, Shuhendler A, Cai P, Rauth AM, Wu XY. Doxorubicin and mitomycin c co-loaded polymer-lipid hybrid nanoparticles inhibit growth of sensitive and multidrug resistant human mammary tumor xenografts. Cancer Lett 2013; 334(2): 263-73.
[105]
Zhang RX, Cai P, Zhang T, et al. Polymer-lipid hybrid nanoparticles synchronize pharmacokinetics of co-encapsulated doxorubicin-mitomycin c and enable their spatiotemporal co-delivery and local bioavailability in breast tumor. Nanomed: Nanotechnol Biol Med 2016; 12(5): 1279-90.
[106]
Hasenstein JR, Shin H-C, Kasmerchak K, Buehler D, Kwon GS, Kozak KR. Anti-tumor activity of triolimus: a novel multi-drug loaded micelle containing paclitaxel, rapamycin and 17-Aag. Mol Cancer Ther 2012; 11(10): 2233-42.
[107]
Yu D, Li W, Zhang Y, Zhang B. Anti-tumor efficiency of paclitaxel and dna when co-delivered by ph responsive ligand modified nanocarriers for breast cancer treatment. Biomed Pharmacother 2016; 83: 1428-35.
[108]
Rong L, Zhou S, Liu X, et al. Trastuzumab-modified dm1-loaded nanoparticles for HER2(+) breast cancer treatment: an in Vitro and in Vivo Study. Artif Cells Nanomed Biotechnol 2017; 46(8): 1-11.
[109]
Varshosaz J, Davoudi MA, Rasoul-Amini S. Docetaxel-loaded nanostructured lipid carriers functionalized with trastuzumab (herceptin) for HER2-positive breast cancer cells. J Liposome Res 2017; 28(4): 1-11.
[110]
Li L, Tong R, Li M, Kohane DS. Self-assembled gemcitabine-gadolinium nanoparticles for magnetic resonance imaging and cancer therapy. Acta Biomater 2016; 33: 34-9.
[111]
De Souza Albernaz M, Toma SH, Clanton J, Araki K, Santos-Oliveira R. Decorated superparamagnetic iron oxide nanoparticles with monoclonal antibody and diethylene-triamine-pentaacetic acid labeled with thechnetium-99m and galium-68 for breast cancer imaging. Pharm Res 2018; 35(1): 24.
[112]
Tezuka K, Takashima T, Kashiwagi S, et al. Phase I study of nanoparticle albumin-bound paclitaxel, carboplatin and trastuzumab in women with human epidermal growth factor receptor 2-overexpressing breast cancer. Mol Clin Oncol 2017; 6(4): 534-8.
[113]
Lee JH, Nan A. Combination drug delivery approaches in metastatic breast cancer. J Drug Deliv 2012; 2012: 17.
[114]
Hu C-MJ, Zhang L. Nanoparticle-based combination therapy toward overcoming drug resistance in cancer. Biochem Pharmacol 2012; 83(8): 1104-11.
[115]
Sparreboom A, Baker SD, Verweij J. Paclitaxel in an albumin-stabilized nanoparticle: handy or just a dandy? J Clin Oncol 2005; 23(31): 7765-7.
[116]
Akala EO, Okunola O. aNovel stealth degradable nanoparticles
fabricated by dispersion polymerization
for the delivery of bioactive agents. Part I Pharm Ind
2013; 75(7): 1191-6. bNovel stealth degradable nanoparticles
fabricated by dispersion polymerization for
the delivery of bioactive agents. Part II Pharm Ind
2013; 75(8): 1346 52.
[117]
Adesina SK, Wight SA, Akala EO. Optimization of the fabrication of novel stealth PLA-based nanoparticles by dispersion polymerization using D-optimal mixture design. Drug Dev Ind Pharm Drug Dev Ind Pharm 2014; 40(11): 1547-56.
[118]
Adesina SK, Holly A, Kramer-Marek G, Capala J, Akala EO. Polylactide based paclitaxel loaded nanoparticles fabricated by dispersion polymerization: characterization, evaluation in cancer cell lines, and preliminary biodistribution studies. J Pharm Sci 2014; 103(8): 2546-55.
[119]
Ogunwuyi O, Adesina SK, Akala EO. D-optimal mixture experimental design for stealth biodegradable crosslinked docetaxel-loaded poly-E-caprolactone nanoparticles fabricated by dispersion polymerization. Pharmazie 2015; 70: 165-76.
[120]
Oluwaseun O, Namita K, Kahli AS, et al. Antiretroviral drugs-loaded nanoparticles fabricated by dispersion polymerization with potential for HIV/AIDS treatment. Infect Dis: Res Treat 2016; 9: 21-32.
[121]
Puri R, Berhe SA, Akala EO. pH-sensitive polymeric nanoparticles fabricated by dispersion polymerization for the delivery of bioactive agents. Pharm Nanotechnol 2017; 5: 1-28.
[122]
Reema Puri, Simeon Adesina, Emmanuel Akala Cellular
uptake and cytotoxicity studies of pH-responsive
polymeric nanoparticles fabricated by dispersion
polymerization. J Nanosci Nanomed 2018; 2(1): 1-
18-2018.
[123]
von Roemeling C, Jiang W, Chan CK, Weissman IL, Kim BY. Breaking down the barriers to precision cancer nanomedicine. Trends Biotechnol 2017; 35(2): 159-71.
[124]
Desai N. (2012) Challenges in development of nanoparticle-based therapeutics. AAPS J 2012; 14: 282-95.
[125]
Emmanuel OA, Simeon KA. Fabrication of polymeric core-shell nanostructures. In: Alexandru Mihai
Grumezescu, Ed. Nanoscale fabrication, optimization, scale-up and biological aspects of pharmaceutical nanotechnology. Elsevier: Oxford 2017; pp. 1-49.
[126]
Choi HS, Ipe BI, Misra P, Lee JH, Bawendi MG, Frangioni JV. Tissue-and organ-selective biodistribution of NIR fluorescent quantum dots. Nano Lett 2009; 9(6): 2354-9.
[127]
Harris JM, Chess RB. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2003; 2: 214-21.
[128]
Schöttler S, Becker G, Winzen S, et al. Protein adsorption is required for stealth effect of poly(ethylene glycol)- and poly(phosphoester)-coated Nanocarriers. Nat Nanotechnol 2016; 11: 372-7.
Call for Papers in Thematic Issues
04 December, 2024
Polymeric nanocarriers in drug delivery
Polymeric nanocarriers play a crucial role in drug delivery due to their versatility, and unique properties for targeting and modifying drug release. Their ability to enhance therapeutic outcomes, reduce side effects, and enable the delivery of drugs in a more targeted and controlled manner made them popular in the last ...read more
Related Books
The Art of Nanomaterials
Advanced Materials and Nano Systems: Theory and Experiment - Part 2
Advanced Materials and Nano Systems: Theory and Experiment (Part-1)
Artificial Intelligence for Smart Cities and Villages: Advanced Technologies, Development, and Challenges
SILVER NANOPARTICLES: Synthesis, Functionalization and Applications
Article Metrics
107
17